Doxorubicin-SMCC is a drug-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin[1].
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
















